From: Clinical study of a new skin antiseptic olanexidine gluconate in gastrointestinal cancer surgery
Patient characteristics | OLG group (n = 223) | Control group (n = 58) | P value |
---|---|---|---|
Mean age (range) | 73.2 ± 10.7 | 73.9 ± 10.2 | 0.853 |
Gender | 0.455 | ||
M | 133 (59.6%) | 31 (53.4%) | |
F | 90 (40.4%) | 27 (46.6%) | |
Mean BMI ± SD | 22.1 ± 3.5 | 22.4 ± 3.7 | 0.6 |
Diabetes mellitus (%) | 66 (29.6%) | 19 (32.8%) | 0.634 |
Alb | 3.89 ± 0.52 | 3.86 ± 0.57 | 0.752 |
Respiratory disease | 39 (17.5%) | 8 (13.8%) | 0.56 |
Anticoagulant | 41 (16.7%) | 10 (17.2%) | 1 |
Primary lesion | 1 | ||
Stomach | 66 (29.6%) | 17 (29.3%) | |
Colon | 157 (70.4%) | 41 (70.7%) | |
ASA | 0.495 | ||
1.2 | 171 (76.7%) | 42 (72.4%) | |
3 | 52 (23.3%) | 16 (27.6%) | |
Mean operation time ± SD | 303.0 ± 108.8 | 297.2 ± 134.9 | 0.732 |
Bleeding (ml) | 130.4 ± 244.5 | 133.3 ± 152.8 | 0.932 |
Approach | 0.000171 | ||
Open | 91 (43.8%) | 42 (72.4%) | |
Laparoscopy | 117 (56.2%) | 16 (27.6%) | |
Transfusion | 5 (2.3%) | 1 (1.7%) | 1 |
Stage | 0.641 | ||
0, I, II | 150 (67.3%) | 37 (63.8%) | |
III, IV | 73 (32.7%) | 21 (36.2%) | |
Leakage | 4 (1.8%) | 5 (8.6%) | 0.0205 |
Complication except SSI | 51 (22.9%) | 18 (31.0%) | 0.232 |
Postoperative length of hospital stay (days) | 15.8 ± 10.4 | 20.0 ± 15.8 | 0.0136 |
Adverse skin reaction (all) | 4 (1.8%) | 3 (5.2%) | 0.157 |
Skin irritation | 2 (0.9%) | 0 (0%) | 1 |
Erythema | 3 (1.3%) | 3 (5.2%) | 0.105 |
Pruritus | 1 (0.4%) | 1 (1.7%) | 0.371 |